IDE397-001

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and anti-tumor activity of IDE397 as a single agent and in combination with docetaxel, paclitaxel, gemcitabine/nab-paclitaxel and pemetrexed in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy or for whom no curative therapy is available. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Acronym:

IDE397-001

ACTRN/NCT /ethics:

NCT04794699

Scientific title:

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Sponsor / Cooperative group:

IDEAYA Biosciences